Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data

Executive Summary

Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.
Advertisement

Related Content

Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says
Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says
Genentech Xanelim Therapy Transition Study To Support Product Launch
Genentech Xanelim Therapy Transition Study To Support Product Launch
Genentech/Novartis Xolair Indication Narrowed To Adult Allergic Asthma
United Therapeutics Remodulin Decision Expected Soon After Cmte. Review
Genentech/Idec Rituxan Letter Warns Of Fatal Mucocutaneous Reactions
Wall Street Not Ready To Go Out On A Limb For Xoma/Genetech Xanelim
Genentech Rituxan Promo Effort To Expand With Broader Lymphoma Label
Genentech Rituxan Promo Effort To Expand With Broader Lymphoma Label
Advertisement
UsernamePublicRestriction

Register

PS038177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel